Proactive Investors - Run By Investors For Investors

PreveCeutical Medical unveils promising findings from non-addictive analgesics program

The firm is developing therapies using organic and nature identical products
PreveCeutical Medical unveils promising findings from non-addictive analgesics program
The company currently has five research and development programs on the go

Health sciences group PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.

The firm is developing therapies using organic and nature identical products.

READ: PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

One of its programs is for non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone.

Preveceutical said that via a meticulous process it had now identified five novel peptide constructs, which preferentially target the receptor subtype which is of interest to the company and is purported to avoid addictive and tolerance-inducing side effects.

This subset of peptides has demonstrated potency, in a well-accepted functional dose response assay, that is on par with clinically available agents, such as morphine, the company added.

Chief research officer Dr Harendra Parekh told investors: "We are very pleased with this promising development, as a result of numerous iterations between our peptide design and cell-based screening efforts, we have now yielded a number of constructs which discriminate between the key pain receptors in the body, and importantly, avoid activation of those purported to lead to dependence."

Preveceutical shares in Toronto were unchanged at $0.06 each.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
glasshouse
January 08 2019
Its plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use